Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Roche Holding — Chugai

Tracked across 3 events · 36 articles · First seen May 18, 2026 · Last active Sep 10, 2026

Sentiment
-5
Attention
6
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 15
Regulatory
Roche announced on 10 September 2026 that the United States — Food and Drug Administration has granted Priority Review to a supplemental Biologics License Application for Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein…
Impact: Chugai developed Enspryng and is a Roche Group member, so a successful MOGAD approval would support its antibody franchise and royalty economics.
Sep 09, 2026 · 6 articles
4 -30
International
Impact: Roche Holding — Chugai's stock tumbled, contributing to the list of major losers.
May 18, 2026 · 23 articles
6 0
Tech
Impact: Roche Holding — Chugai is a major innovator in the Japanese therapeutic antibody market and Roche is its majority shareholder. This event does not directly impact Roche Holding — Chugai.
Jun 29, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Roche Holding — Chugai live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.